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1. INTRODUCTION {#jcla23022-sec-0005}
===============

Antineutrophil cytoplasmic antibody (ANCA)‐associated vasculitis (AAV) is a group of three systemic vasculitides involving small vessels, such as microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA) according to the 2012 Chapel Hill Consensus Conferences Nomenclature of Vasculitis (the 2012 CHCC definitions).[1](#jcla23022-bib-0001){ref-type="ref"} On the basis of small‐vessel necrotizing vasculitis, MPA mainly provokes necrotizing glomerulonephritis and pulmonary capillaritis and GPA often causes granuloma formation of the upper and lower respiratory tracts and occasionally necrotizing glomerulonephritis. Meanwhile, EGPA is characterized by three typical allergic components including asthma, peripheral eosinophilia, and eosinophil‐rich granuloma of the respiratory tracts.[1](#jcla23022-bib-0001){ref-type="ref"}, [2](#jcla23022-bib-0002){ref-type="ref"}

A natural history of AAV was previously reported. The first‐year and the second‐year mortality rates were 82% and 90%, and the main etiology of mortality was uremia as a result of rapidly progressive glomerulonephritis.[3](#jcla23022-bib-0003){ref-type="ref"} As various therapeutic regimens were developed and widely used, the first‐year mortality rate was remarkably decreased to \<10%‐20%.[4](#jcla23022-bib-0004){ref-type="ref"}, [5](#jcla23022-bib-0005){ref-type="ref"} Nevertheless, any delayed initiation of induction therapy for severe AAV potentially causes irreversible organ damages, which is eventually jeopardizing the quality of life. Therefore, the early diagnosis and treatment for AAV are required and the proper selection of therapeutic regimens should be carefully chosen based on the stage of the disease and its severity. Furthermore, the first treatment should be targeted for induction of remission.[2](#jcla23022-bib-0002){ref-type="ref"}

Birmingham Vasculitis Activity Score (BVAS) has been used for assessing the activity and severity of AAV, and it was reportedly associated with the poor prognosis of AAV.[6](#jcla23022-bib-0006){ref-type="ref"}, [7](#jcla23022-bib-0007){ref-type="ref"} Five‐factor score (FFS; 2009) was also used to predict the poor prognosis.[8](#jcla23022-bib-0008){ref-type="ref"} Besides BVAS and FFS (2009), several other indices have been applied to Korean patients with AAV, in order to estimate AAV activity at diagnosis and predict the poor prognosis. However, there has been no tool to estimate AAV activity at diagnosis and predict all‐cause mortality in patients with AAV, and thus, there has been a great need for a new AAV‐specific index for assessing the cross‐sectional activity at diagnosis and predicting the prognosis during follow‐up in patients with AAV. To elucidate these issues, in this study, we screened variables at diagnosis which were associated with severe AAV and determined the initial predictors of the cross‐sectional activity at diagnosis and all‐cause mortality during follow‐up in immunosuppressive drug‐naïve patients with AAV.

2. MATERIALS AND METHODS {#jcla23022-sec-0006}
========================

2.1. Patients {#jcla23022-sec-0007}
-------------

We retrospectively screened the medical records of 209 patients with AAV and reviewed those of 182 patients with AVV, who met the conditions as follows: (a) the first classification as AAV at the Division of Rheumatology, the Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital from October 2000 to April 2018; (b) the fulfillment of the American College of Rheumatology 1990 criteria for GPA and EGPA and then the reclassification as AAV by the 2007 European Medicines Agency algorithm and the 2012 CHCC definitions[1](#jcla23022-bib-0001){ref-type="ref"}, [9](#jcla23022-bib-0009){ref-type="ref"}, [10](#jcla23022-bib-0010){ref-type="ref"}, [11](#jcla23022-bib-0011){ref-type="ref"}; (c) the follow‐up duration of at least three months or greater; (d) the well‐documented medical records precise enough to assess calculate BVAS and FFS (2009)[6](#jcla23022-bib-0006){ref-type="ref"}, [8](#jcla23022-bib-0008){ref-type="ref"}; (e) the presence of the results of perinuclear (P)‐ANCA and cytoplasmic (C)‐ANCA or myeloperoxidase (MPO)‐ANCA and proteinase 3 (PR3)‐ANCA at diagnosis[12](#jcla23022-bib-0012){ref-type="ref"}; (f) no other medical conditions at diagnosis to confuse the classification of AAV, which were identified by the 10th revised International Classification of Diseases (ICD‐10)[13](#jcla23022-bib-0013){ref-type="ref"}; and (g) no history of immunosuppressive drugs prior to or at diagnosis of AAV, which was verified by the Korean Drug Utilisation Review (DUR) system. This study was approved by the Institutional Review Board (IRB) of Severance Hospital (4‐2017‐0673), and the patient\'s written informed consent was waived by the approving IRB, as this was a retrospective study.

2.2. Data at diagnosis of AAV {#jcla23022-sec-0008}
-----------------------------

We obtained age at diagnosis and gender in patients with AAV. We reviewed clinical manifestations and laboratory data at diagnosis and then calculated BVAS and FFS (2009). We collected laboratory results at diagnosis, such as white blood cell, neutrophil, lymphocyte and platelet counts, hemoglobin, prothrombin time (international normalized ratio, INR), fasting glucose, blood urea nitrogen, creatinine, total protein, serum albumin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, total bilirubin, erythrocyte sedimentation rate (ESR), and C‐reactive protein (CRP).

2.3. Data during follow‐up {#jcla23022-sec-0009}
--------------------------

We defined the follow‐up duration as the period from diagnosis to the last visit for patients with remission and/or survived patients, and we defined it as the period from diagnosis to death for deceased patients. Since chronic kidney disease, end‐stage renal disease, ischemic heart disease, congestive heart failure, interstitial lung disease, and cerebrovascular disease belong to items of BVAS, we also counted the number of patients with diabetes mellitus and hypertension among comorbidities. We reviewed the administration of immunosuppressive drugs during follow‐ups such as glucocorticoid, cyclophosphamide, azathioprine, rituximab, methotrexate, mycophenolate mofetil, and tacrolimus. Death was defined as all‐cause mortality.

2.4. Severe AAV {#jcla23022-sec-0010}
---------------

We stratified patients with AAV into three groups based on the tertile of BVAS and defined the lower limit of the highest tertile as the cutoff for the current severe AAV (BVAS at diagnosis ≥16).

2.5. Statistical analyses {#jcla23022-sec-0011}
-------------------------

All statistical analyses were conducted using SPSS software (version 23 for Windows; IBM Corp). Continuous variables were expressed as a median (interquartile range, IQR), and categorical variables were expressed as number and the percentage. Significant differences in categorical variables between the two groups were analyzed using chi‐square and Fisher\'s exact tests. Significant differences in continuous variables between the two groups were compared using the Mann‐Whitney test. The optimal cutoffs of laboratory variables at diagnosis for severe AAV were extrapolated by calculating the area under the receiver operator characteristic curve (AUROC) and selecting the point to maximize the sum of sensitivity and specificity. The odds ratio (OR) was assessed using the multivariable logistic regression analysis of variables with *P* values \<.05 on the univariable logistic regression analysis. The relative risk (RR) of the optimal cutoff was analyzed using contingency tables and the chi‐square test. Comparison of cumulative patient survival between the two groups was analyzed by the Kaplan‐Meier survival analysis. In this study, *P* values less than 0.05 were considered statistically significant.

3. RESULTS {#jcla23022-sec-0012}
==========

3.1. Baseline characteristics of patients with AAV {#jcla23022-sec-0013}
--------------------------------------------------

Demographic, clinical, and laboratory data at diagnosis of AAV were described in Table [1](#jcla23022-tbl-0001){ref-type="table"}. The most common clinical manifestation at diagnosis was renal involvement (58.2%), followed by pulmonary involvement (56.0%). The median BVAS and FFS (2009) at diagnosis were 12.0 (11.0) and 1.0 (1.0), respectively. The median values of laboratory results were shown in Table [1](#jcla23022-tbl-0001){ref-type="table"}. During the follow‐up of the median duration of 39.5 (72.0) months, 36 patients (19.8%) had diabetes mellitus and 76 patients (41.8%) had hypertension. The most frequently administered immunosuppressive drug was glucocorticoid (86.8%), followed by cyclophosphamide (41.8%) and azathioprine (53.3%). Fifteen patients (8.2%) died of all etiologies during follow‐up (Table [1](#jcla23022-tbl-0001){ref-type="table"}).

###### 

Characteristics of 182 patients with AAV at diagnosis and during follow‐up

  Variables                                                 Values
  --------------------------------------------------------- -----------------
  At diagnosis                                              
  Demographic data at diagnosis                             
  Age (year old)                                            58.5 (21.0)
  Male gender (N, \[%\])                                    55 (30.2)
  Variants of AAV                                           
  MPA                                                       97 (53.3)
  GPA                                                       45 (24.7)
  EGPA                                                      40 (22.0)
  ANCA at diagnosis (N, \[%\])                              
  MPO‐ANCA (or P‐ANCA)                                      117 (64.3)
  PR3‐ANCA (or C‐ANCA)                                      30 (16.5)
  MPO‐ANCA (or P‐ANCA) and PR3‐ANCA (or C‐ANCA)             9 (4.9)
  ANCA negativity                                           44 (24.2)
  Clinical manifestations at diagnosis (N, \[%\])           
  Renal                                                     106 (58.2)
  Pulmonary                                                 102 (56.0)
  General                                                   80 (44.0)
  Ear Nose Throat                                           68 (37.4)
  Nervous system                                            56 (30.8)
  Cardiovascular                                            47 (25.8)
  Cutaneous                                                 41 (22.5)
  Mucous membranes/eyes                                     12 (6.6)
  Gastrointestinal                                          10 (5.5)
  Vasculitis activity and prognostic factors at diagnosis   
  BVAS or BVAS for GPA                                      12.0 (11.0)
  FFS (2009)                                                1.0 (1.0)
  Laboratory results at diagnosis                           
  White blood cell (/mm^3^)                                 9260.0 (6425.0)
  Neutrophil (/mm^3^)                                       6510.0 (6000.0)
  Lymphocyte (/mm^3^)                                       1480.0 (980.0)
  Hemoglobin (g/dL)                                         11.6 (3.7)
  Platelet (×1000/mm^3^)                                    307.5 (164.5)
  Prothrombin time (INR)                                    1.0 (0.2)
  Fasting glucose (mg/dL)                                   101.0 (34.0)
  Blood urea nitrogen (mg/dL)                               17.4 (19.4)
  Creatinine (mg/dL)                                        1.0 (1.3)
  Total protein (g/dL)                                      6.6 (1.3)
  Serum albumin (g/dL)                                      3.6 (1.1)
  Alkaline phosphatase (IU/L)                               68.5 (37.3)
  Aspartate aminotransferase (IU/L)                         18.0 (8.0)
  Alanine aminotransferase (IU/L)                           15.0 (14.0)
  Total bilirubin (mg/dL)                                   0.5 (0.2)
  ESR (mm/h)                                                57.5 (70.0)
  CRP (mg/L)                                                14.5 (60.2)
  During follow‐up                                          
  Follow‐up duration (mo)                                   39.5 (72.0)
  Comorbidities (N, \[%\])                                  
  Diabetes mellitus                                         36 (19.8)
  Hypertension                                              76 (41.8)
  Immunosuppressive drugs (N, \[%\])                        
  Glucocorticoid                                            158 (86.8)
  Cyclophosphamide                                          76 (41.8)
  Azathioprine                                              97 (53.3)
  Rituximab                                                 19 (10.4)
  Methotrexate                                              13 (7.1)
  Mycophenolate mofetil                                     10 (5.5)
  Tacrolimus                                                9 (4.9)
  Prognosis (N, \[%\])                                      
  All‐cause mortality                                       15 (8.2)

Values are expressed as a median (interquartile range \[IQR\]) or N (%).

Abbreviations: AAV, antineutrophil cytoplasmic antibody (ANCA)‐associated vasculitis; ANCA, antineutrophil cytoplasmic antibody; BVAS, Birmingham Vasculitis Activity Score; C‐ANCA, cytoplasmic ANCA; CRP, C‐reactive protein; EGPA, eosinophilic granulomatosis with polyangiitis; ESR, erythrocyte sedimentation rate; FFS, five‐factor score; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; MPO, myeloperoxidase; P‐ANCA, perinuclear ANCA; PR3, proteinase 3; WBC, white blood cell.
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3.2. Comparison of laboratory variables at diagnosis between AAV patients with and without severe AAV {#jcla23022-sec-0014}
-----------------------------------------------------------------------------------------------------

Sixty‐three patients had BVAS more than 16 and were classified as severe AAV. There were no differences in age and gender between the two groups. Because clinical manifestations at diagnosis were based on all items of BVAS, as was expected, patients with BVAS at diagnosis ≥16 exhibited the higher frequencies of renal, pulmonary, general, cardiovascular, and gastrointestinal manifestations than those without. Compared with non‐severe AAV patients, patients with severe AAV had the increased median neutrophil count, platelet count, blood urea nitrogen, creatinine, ESR, and CRP than those without. On the other hands, patients with severe AAV exhibited the lower median lymphocyte count, hemoglobin, and serum albumin than those without (Table [2](#jcla23022-tbl-0002){ref-type="table"}). As there was collinearity between blood urea nitrogen and creatinine, we excluded it in the following analyses.

###### 

Comparison of laboratory variables at diagnosis between AAV patients with and without BVAS at diagnosis ≥16

  Variables                                         Patients with BVAS at diagnosis ≥16 (N = 63)   Patients with BVAS at diagnosis \< 16 (N = 119)   *P* value
  ------------------------------------------------- ---------------------------------------------- ------------------------------------------------- -----------
  Demographic data at diagnosis                                                                                                                      
  Age (year old)                                    62.0 (23.0)                                    56.0 (21.0)                                       .057
  Male gender (N, \[%\])                            16 (25.4)                                      39 (32.8)                                         .303
  Clinical manifestations at diagnosis (N, \[%\])                                                                                                    
  Renal                                             55 (87.3)                                      51 (42.9)                                         \<.001
  Pulmonary                                         42 (66.7)                                      60 (50.4)                                         .036
  General                                           39 (61.9)                                      41 (34.5)                                         \<.001
  Ear Nose Throat                                   21 (33.3)                                      47 (39.5)                                         .414
  Nervous system                                    23 (36.5)                                      33 (27.7)                                         .222
  Cardiovascular                                    28 (44.4)                                      19 (16.0)                                         \<.001
  Cutaneous                                         16 (25.4)                                      25 (21.0)                                         .500
  Mucous membranes/eyes                             4 (6.3)                                        8 (6.7)                                           .923
  Gastrointestinal                                  7 (11.1)                                       3 (2.5)                                           .016
  Laboratory results at diagnosis                                                                                                                    
  White blood cell (/mm^3^)                         10 470.0 (7210.0)                              9040.0 (5600.0)                                   .097
  Neutrophil (/mm^3^)                               7640.0 (6000.0)                                5440.0 (5000.0)                                   .025
  Lymphocyte (/mm^3^)                               1210.0 (780.0)                                 1580.0 (980.0)                                    .033
  Hemoglobin (g/dL)                                 9.9 (3.2)                                      12.3 (3.1)                                        \<.001
  Platelet (×1000/mm^3^)                            337.0 (256.5)                                  301.0 (143.5)                                     .032
  Prothrombin time (INR)                            1.0 (0.2)                                      1.0 (0.2)                                         .310
  Fasting glucose (mg/dL)                           100.0 (33.0)                                   101.0 (34.0)                                      .896
  Blood urea nitrogen (mg/dL)                       24.6 (23.8)                                    15.2 (11.8)                                       .002
  Creatinine (mg/dL)                                1.4 (2.1)                                      1.2 (0.7)                                         .010
  Total protein (g/dL)                              6.4 (1.2)                                      6.8 (1.1)                                         .910
  Serum albumin (g/dL)                              3.3 (1.4)                                      3.8 (1.1)                                         \<.001
  Alkaline phosphatase (IU/L)                       68.0 (40.0)                                    69.0 (35.0)                                       .745
  Aspartate aminotransferase (IU/L)                 17.0 (9.0)                                     18.0 (8.0)                                        .468
  Alanine aminotransferase (IU/L)                   14.0 (16.0)                                    17.0 (13.3)                                       .751
  Total bilirubin (mg/dL)                           0.4 (0.3)                                      0.5 (0.2)                                         .361
  ESR (mm/h)                                        69.0 (88.0)                                    49.0 (59.0)                                       .005
  CRP (mg/L)                                        27.2 (90.0)                                    7.5 (41.7)                                        .015

Values are expressed as a median (interquartile range \[IQR\]) or N (%).

Abbreviations: AAV, antineutrophil cytoplasmic antibody (ANCA)‐associated vasculitis; ANCA, antineutrophil cytoplasmic antibody; BVAS, Birmingham Vasculitis Activity Score; CRP, C‐reactive protein; ESR, erythrocyte sedimentation rate.

Because blood urea nitrogen is closely related to creatinine, we included only creatinine in the analysis.

John Wiley & Sons, Ltd

3.3. Optimal cutoffs of laboratory variables for severe AAV at diagnosis {#jcla23022-sec-0015}
------------------------------------------------------------------------

We obtained the optimal cutoffs of laboratory variables at diagnosis for severe AAV, which were significant in the comparative analysis between patients with and without severe AAV. The optimal cutoffs of variables are as below: neutrophil count ≥ 7570.0/mm^3^; lymphocyte count ≤ 1430.0/mm^3^; hemoglobin ≤ 10.8 g/dL; platelet count ≥ 352 500.0/mm^3^; creatinine ≥ 0.9 mg/dL; serum albumin ≤ 3.5 g/dL; ESR ≥ 83.5 mm/h; and CRP ≥ 20.0 mg/L (Table [S1](#jcla23022-sup-0004){ref-type="supplementary-material"}). Although platelet count exhibited no statistical significance (area 0.568, 95% confidence interval (CI) 0.475, 0.661), we included platelet count ≥ 352 500.0/mm^3^ in the logistic regression analyses, because it significantly differed between patients with and without severe AAV in the comparison analysis.

3.4. Univariable and multivariable logistic regression analyses for severe AAV at diagnosis {#jcla23022-sec-0016}
-------------------------------------------------------------------------------------------

Since there were no significant differences in age at diagnosis and gender between the two groups, we did not include them in the univariable and multivariable logistic regression analyses. In the univariable logistic regression analysis of laboratory variables at diagnosis for severe AAV, all laboratory variables with significance in the comparative analysis exhibited significant ORs: neutrophil count ≥ 7570.0/mm^3^ (OR 2.499); lymphocyte count ≤ 1430.0/mm^3^ (OR 2.664); hemoglobin ≤ 10.8 g/dL (OR 4.348); platelet count ≥ 352 500.0/mm^3^ (OR 2.325); creatinine ≥ 0.9 mg/dL (OR 3.536); serum albumin ≤ 3.5 g/dL (OR 2.770); ESR ≥ 83.5 mm/h (OR 3.051); and CRP ≥ 20.0 mg/L (OR 2.770; Table [3](#jcla23022-tbl-0003){ref-type="table"}). In the multivariable logistic regression analysis of laboratory variables at diagnosis for severe AAV, only creatinine ≥ 0.9 mg/dL was significantly associated with severe AAV at diagnosis (OR 2.264, 95% CI 1.107, 5.040). In addition, lymphocyte count ≤ 1430.0/mm^3^ and hemoglobin ≤ 10.8 g/dL also tended to be associated with severe AAV at diagnosis (OR 1.856, 95% CI 0.906, 3.804 and OR 2.085, 95% CI 0.917, 4.737, respectively; Table [3](#jcla23022-tbl-0003){ref-type="table"}). We derived an equation of a multivariable index for AAV (MVIA) using lymphocyte count, hemoglobin, and creatinine with *P* value \< .01 in the multivariable logistic regression analysis.

###### 

Logistic regression analyses for severe AAV at diagnosis

  Variables at diagnosis        Univariable   Multivariable                                           
  ----------------------------- ------------- --------------- -------- ------- ------- -------------- ------
  Neutrophil ≥7570.0/mm^3^      2.499         1.334, 4.681    .004     0.332   1.394   0.627, 3.099   .416
  Lymphocyte ≤ 1430.0/mm^3^     2.664         1.418, 5.007    .002     0.619   1.856   0.906, 3.804   .091
  Hemoglobin ≤ 10.8 g/dL        4.348         2.272, 8.320    .001     0.735   2.085   0.917, 4.737   .079
  Platelet ≥ 352 500.0/mmy^3^   2.325         1.236, 4.374    .009     0.448   1.566   0.624, 3.931   .340
  Creatinine ≥ 0.9 mg/dL        3.536         1.805, 6.926    \<.001   0.817   2.264   1.107, 5.040   .045
  Serum albumin ≤ 3.5 g/dL      2.770         1.475, 5.202    .002     0035    1.036   0.457, 2.348   .933
  ESR ≥ 83.5 mm/h               3.051         1.578, 5.898    .001     0.507   1.660   0.682, 4.045   .264
  CRP ≥ 20.0 mg/L               2.770         1.475, 5.202    .002     0.023   1.023   0.427, 2.452   .960

Abbreviations: AAV, antineutrophil cytoplasmic antibody (ANCA)‐associated vasculitis; ANCA, antineutrophil cytoplasmic antibody; CRP, C‐reactive protein; ESR, erythrocyte sedimentation rate.

John Wiley & Sons, Ltd

3.5. Equation of MVIA {#jcla23022-sec-0017}
---------------------

We assigned a weight of a number close to an integer to each variable according to the slopes for independent variable with *P* value \< .1 in the multivariable logistic regression analysis: *B* = 0.6 for Lymphocyte ≤ 1430.0/mm^3^, *B* = 0.7 for Hemoglobin ≤ 10.8 g/dL, and *B* = 0.8 for Creatinine ≥ 0.9 mg/dL (Table [3](#jcla23022-tbl-0003){ref-type="table"}). And we developed a new equation as follows: a multivariable index for AAV (MVIA) = 0.6 × (Lymphocyte ≤ 1430.0/mm^3^: yes = 1 or no = 0) + 0.7 × (Hemoglobin ≤ 10.8 g/dL: yes = 1 or no = 0) + 0.8 × (Creatinine ≥0.9 mg/dL: yes = 1 or no = 0). For instance, if a patient had lymphocyte ≤ 1430.0/mm^3^, hemoglobin ≤ 10.8 g/dL, and creatinine ≥ 0.9 mg/dL, that patient would have MVIA of 2.1 (0.6 × 1 + 0.7 × 1 + 0.8 × 1).

3.6. Optimal cutoff of MVIA for severe AAV {#jcla23022-sec-0018}
------------------------------------------

The median calculated MVIA was 0.8 with IQR of 1.5. The maximum and minimum MVIA were 2.1 and 0, respectively. MVIA was positively correlated with BVAS at diagnosis (*r* = 0.370, *P* \< .001). We also obtained the optimal cutoff of MVIA for severe AAV as 1.35 (sensitivity 0.667 and specificity 0.689) using the AUROC curve (area 0.727, 95% CI 0.648, 0.805; Figure [1](#jcla23022-fig-0001){ref-type="fig"}A). When we divided patients with AAV into the two groups based on the optimal cutoff of MVIA for severe AAV, 79 patients belonged to the group of MVIA at diagnosis ≥1.35. The cross‐sectional severe AAV appeared more frequently in patients with MVIA at diagnosis ≥1.35 than those without (53.2% vs 20.4%, *P* \< .001). In addition, patients with MVIA at diagnosis ≥1.35 exhibited a significantly high RR for severe AAV at diagnosis, compared to those without (RR 4.432, 95% CI 2.309, 8.507; Figure [1](#jcla23022-fig-0001){ref-type="fig"}B).

![Optimal cutoff of MVIA for severe AAV. A, The optimal cutoff of MVIA at diagnosis for severe AAV was obtained as 1.35 (sensitivity 0.667 and specificity 0.689). B, Patients with MVIA at diagnosis ≥1.35 exhibited a significantly high RR for severe AAV at diagnosis, compared to those without (RR 4.432, 95% CI 2.309, 8.507). AAV, antineutrophil cytoplasm antibody (ANCA)‐associated vasculitis; CI, confidence interval; MVIA, a multivariable index for AAV; RR, relative risk](JCLA-34-e23022-g001){#jcla23022-fig-0001}

3.7. Cumulative patient survival rate {#jcla23022-sec-0019}
-------------------------------------

We investigated the cumulative patient survival rate during follow‐up between patients with and without MVIA at diagnosis ≥1.35. Patients with MVIA at diagnosis ≥1.35 exhibited the lower cumulative patient survival rate than those with MVIA \<1.35 (*P* = .006). We also applied the Kaplan‐Meier survival analysis to all laboratory variables having optimal cutoffs and found only hemoglobin at diagnosis ≤10.8 g/dL was significantly associated with all‐cause mortality in patients with AAV (*P* = .006; Figure [2](#jcla23022-fig-0002){ref-type="fig"}).

![All‐cause mortality rate. Patients with MVIA at diagnosis ≥1.35 (*P* = .006) and hemoglobin at diagnosis ≤10.8 g/dL (*P* = .006) were significantly associated with all‐cause mortality in AAV patients. AAV, antineutrophil cytoplasm antibody (ANCA)‐associated vasculitis; MVIA, a multivariable index for AAV](JCLA-34-e23022-g002){#jcla23022-fig-0002}

4. DISCUSSION {#jcla23022-sec-0020}
=============

In this study, we derived a new equation of MVIA using laboratory variables significantly associated with severe AAV at diagnosis and successfully documented that MVIA could assess the cross‐sectional activity and severity at diagnosis and predict all‐cause mortality during follow‐up in immunosuppressive drug‐naïve patients with AAV. First, our findings suggest that patients with severe AAV exhibited the higher median neutrophil count, platelet count, creatinine, ESR, and CRP, and showed the lower median lymphocyte count, hemoglobin, and serum albumin than those without. Second, we obtained the optimal cutoff of each variable with significance in the comparative analysis using the AUROC curve. Third, in the univariable and multivariable logistic regression analysis, we found that lymphocyte count ≤ 1430.0/mm^3^, hemoglobin ≤ 10.8 g/dL, and creatinine ≥ 0.9 mg/dL were meaningfully associated with the cross‐sectional severe AAV. Using these three variables at diagnosis, we derived a new equation of MVIA. The optimal cutoff of MVIA for severe AAV was identified as 1.35. Fourth, the cross‐sectional severe AAV was identified more frequently in patients with MVIA at diagnosis ≥1.35 than those without (RR 4.432, 95% CI 2.309, 8.507). Fifth, in the survival analysis, MVIA at diagnosis ≥1.35 was significantly associated with all‐cause mortality during follow‐up.

Among variables routinely measured at each visit in the clinics, in the univariable analysis, eight variables were associated with severe AAV, and furthermore, in the multivariable analysis, creatinine at diagnosis ≥0.9 mg/dL alone was statistically highly associated with severe AAV. In addition, lymphocyte count ≤ 1430.0/mm^3^ and hemoglobin ≤ 10.8 g/dL also tended to be associated with severe AAV at diagnosis. We explored an index with more than two variables including lymphocyte count ≤ 1430.0/mm^3^, hemoglobin ≤ 10.8 g/dL, and creatinine ≥ 0.9 mg/dL to offset against the high variability in one variable, which eventually could be more stable and reliable. For these reasons, MVIA showed the highest area for severe AAV in the multivariable AUROC curve (area 0.678, 95% CI 0.595, 0.761), compared with other eight variables at diagnosis (Figure [S1](#jcla23022-sup-0001){ref-type="supplementary-material"}).

Why did we need to calculate MVIA at diagnosis, in additional to BVAS at diagnosis? We wondered whether patients with AAV in the present study received the proper induction and maintenance therapies based on the cross‐sectional activity.[2](#jcla23022-bib-0002){ref-type="ref"}, [14](#jcla23022-bib-0014){ref-type="ref"} When we divided patients with AAV into the two groups based on MVIA at diagnosis ≥1.35, 79 patients belonged to the group of MVIA at diagnosis ≥1.35. We compared the use of cyclophosphamide, rituximab, and azathioprine between patients with MVIA at diagnosis ≥1.35 and those without. Cyclophosphamide was administered to patients with MVIA at diagnosis ≥1.35 more frequently than those without (44.7% vs 29.1%, *P* \< .001). Rituximab was evenly administered to both groups. Because only one cycle of rituximab in the whole life can be covered by the Korean National Health Insurance, rituximab might be administered as an induction therapeutic regimen. Azathioprine was also administered to patients with MVIA at diagnosis ≥1.35 more frequently than those without (64.6% vs 44.7%, *P* \< .001). If we had serially noticed the severity of AAV, more aggressive therapies could have been applied to patients with the high severity of AAV. This further highlights our study that MVIA at diagnosis could be used as a supplementary index for severe AAV. In the clinical settings, BVAS might be affected by subjective complaints, such as myalgia or arthralgia, and it needs more tests including echocardiography in a patient suspected of myocarditis. However, since MVIA consists of only laboratory variables, which are routinely measured at every visit, it is more convenient to evaluate the severity of AAV. And furthermore, if we develop an automatic calculator of MVIA, severe AAV based on BVAS may be rapidly and promptly assessed.

So why does MVIA at diagnosis reflects severe AAV based on BVAS at diagnosis? We guessed that MVIA may estimate severe AAV well because its parameters could reflect severe AAV (the high activity of AAV) better than other laboratory values. First, lymphocyte count may also be affected by general health and stress or various autoimmune diseases and we previously proved the lower number of lymphocyte in severe AAV compared with non‐severe AAV.[15](#jcla23022-bib-0015){ref-type="ref"} Second, the reduced hemoglobin was reported to be one of systemic complication of AAV.[16](#jcla23022-bib-0016){ref-type="ref"} Third, serum creatinine level is already included in BVAS as one item, and thus, it is naturally accepted that the serum level of creatinine might be correlated with BVAS well.[6](#jcla23022-bib-0006){ref-type="ref"}

We found that MVIA at diagnosis ≥1.35 was significantly associated with all‐cause mortality. Although the poor prognosis includes various clinical situations such as relapse, renal survival, and all‐cause mortality, we assessed only all‐cause mortality in this study. For, in our retrospective AAV cohort, the clinical significance of BVAS at diagnosis exhibited the difference patterns according to AAV variants: BVAS was associated with relapse of MPA and refractory disease of GPA, but not with the prognosis of EGPA. In this study, BVAS at diagnosis ≥16 could not predict all‐cause mortality in patients with AAV. Whereas, patients with FFS (2009) at diagnosis ≥2 exhibited the higher all‐cause mortality rate than those without during follow‐up (*P* = .001), which is compatible with our previous study.[17](#jcla23022-bib-0017){ref-type="ref"}, [18](#jcla23022-bib-0018){ref-type="ref"}, [19](#jcla23022-bib-0019){ref-type="ref"} On the other hand, MVIA at diagnosis ≥1.35 was significantly associated with all‐cause mortality. In fact, the cutoff of MVIA at diagnosis was derived from severe AAV based on BVAS at diagnosis ≥16 but not based on all‐cause mortality. Nevertheless, MVIA at diagnosis ≥1.35 indeed predicted all‐cause mortality. We assumed that during follow‐up, the effects of each of BVAS items and MVIA variables on all‐cause mortality might have been different. It is assumed that the variables of MVIA may have been essential parameters for predicting all‐cause mortality compared with all items of BVAS. As a result, MVIA at diagnosis could assess the cross‐sectional activity and predict all‐cause mortality better than BVAS at diagnosis.

We also focused on FFS at diagnosis ≥2, developed another new equation of MVIA based on FFS at diagnosis and the predictive value for all‐cause mortality between MVIA based on BVAS and that based on FFS at diagnosis. We obtained the optimal cutoffs of laboratory variables at diagnosis for FFS at diagnosis ≥2. The optimal cutoffs of variables are as below: neutrophil count ≥ 7570.0/mm^3^; lymphocyte count ≤ 1475.0/mm^3^; hemoglobin ≤ 10.8 g/dL; creatinine ≥ 1.16 mg/dL; serum albumin ≤ 3.65 g/dL; and CRP ≥39.35 mg/L (Table [S2](#jcla23022-sup-0005){ref-type="supplementary-material"}). In the univariable logistic regression analysis, significant ORs for FFS at diagnosis ≥2 were found in all variables with the significant cutoffs. In the multivariable logistic regression analysis, neutrophil ≥ 7570.0/mm^3^, hemoglobin ≤ 10.8 g/dL, and creatinine ≥ 1.16 mg/dL were significantly associated with FFS at diagnosis ≥2 (Table [S3](#jcla23022-sup-0006){ref-type="supplementary-material"}). We assigned a weight to each variable according to the slopes and expressed another new MVIA based on FFS at diagnosis = 1.2 × (Neutrophil ≥ 7570.0/mm^3^: yes = 1 or no = 0) + 1.6 × (Hemoglobin ≤ 10.8 g/dL: yes = 1 or no = 0) + 1.9 × (Creatinine ≥ 1.16 mg/dL: yes = 1 or no = 0). In addition, we obtained the optimal cutoff of MVIA for FFS at diagnosis ≥2 as 1.75 (sensitivity 0.667 and specificity 0.689) using the AUROC curve (area 0.850; Figure [S2](#jcla23022-sup-0002){ref-type="supplementary-material"}). We found that MVIA based on FFS at diagnosis ≥1.75 exhibited no significant difference in patient survival rate from MVIA based on FFS at diagnosis \<1.75 (*P* = .072; Figure [S3](#jcla23022-sup-0003){ref-type="supplementary-material"}). Therefore, we conclude that MVIA based on BVAS at diagnosis ≥1.35 could predict all‐cause mortality during follow‐up in patients with AAV than MVIA based on FFS at diagnosis ≥1.75.

Our study has several limitations. This study is based on study population that was not large enough to represent the clinical data of all‐Korean patients with AAV. Also, due to the retrospective study design, the usefulness of MVIA was not explored for assessing the serially changing the cross‐sectional activity and severity of AAV under the administration of immunosuppressive drugs. However, we hope that future nationwide prospective studies with a larger number of patients with AAV could overcome all of these issues.

Our study has several merits. We have first developed an AAV‐specific index for assessing the cross‐sectional activity and severity and predicting all‐cause mortality in patients with AAV. Because we included patients, who had been classified as AAV at the same department of one tertiary hospital, our study was able to minimize the inter‐centric variation. Also, our institute is one of the biggest tertiary university hospitals in Korea, and furthermore, our AAV cohort is the only one in Korea. So, almost all the patients are transferred to our institute when a situation occurs requiring consideration of death in patients with AAV. In addition, we tried to contact patients with AAV, who were not followed up, by phone and so we could precisely confirm all‐cause mortality, although the causes of death were not known in all patients. Lastly, given that the clinical features and the prognosis of AAV may vary based on geographical and ethnic differences, this study first demonstrated the clinical implication of MVIA in Korean patients with AAV.

5. CONCLUSION {#jcla23022-sec-0021}
=============

A new AAV‐specific MVIA could assess the cross‐sectional activity and severity and predict all‐cause mortality in immunosuppressive drug‐naïve patients with AAV during follow‐up.
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